Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia

Rituximab is an effective treatment for autoimmune cytopenias associated with chronic lymphocytic leukemia. Despite the incorporation of rituximab into fludarabine-based chemotherapy regimens, the incidence of autoimmune cytopenias has remained high. Inadequate rituximab exposure due to rapid antibo...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Mo, Clifton C., Njuguna, Ndegwa, Beum, Paul V., Lindorfer, Margaret A., Vire, Berengere, Lee, Elinor, Marti, Gerald, Wilson, Wyndham H, Taylor, Ronald P., Wiestner, Adrian
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Ferrata Storti Foundation 2013
Konular:
Original Articles and Brief Reports
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3729907/
https://ncbi.nlm.nih.gov/pubmed/23716541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.080929
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller